NCT02517788 - Phase I BP Interferon (IFN) Beta-004 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Interferon beta-1a HSA-free biosimilar

6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin

DRUG

Interferon beta-1a HSA+ biosimilar

6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution

DRUG

Interferon beta-1a original

6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)